- N14, ITTC Building, Plymouth Science Park, Plymouth, PL6 8BX
- +44 1752 439829
- camille.carroll@plymouth.ac.uk
Profiles
Dr Camille Carroll
Professor of Clinical Neuroscience
Peninsula Medical School (Faculty of Health)
Dr Camille Carroll can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
- Clinical trials
- Parkinson's disease
- NIHR/CRN
- Neuroprotection
- Remote care pathways
- Neurodegenerative disease
- Health technology
Email publicrelations@plymouth.ac.uk to enquire.
Biography
Biography
- Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust
- National Specialty Lead for Neurodegenerative Diseases NIHR CRN
- Parkinson’s Specialty Lead and Cluster 4 Clinical Research Lead South West Peninsula CRN
- Integrated Clinical Academic Training Lead
Qualifications
Dr Carroll is an academic consultant neurologist. She undertook her preclinical medical training at the University of Manchester, where she also completed an intercalated PhD (1994) investigating NMDA receptor antagonists in models of Parkinson's disease (PD). She completed her clinical training at the University of Oxford in 1997 and undertook specialist neurology training in the South West and West Midlands. In 2007 Dr Carroll was awarded a Medical Research Council fellowship which allowed her to develop research interests investigating neuroprotective mechanisms in cell culture models of Parkinson's disease.
Roles on external bodies
Dr Carroll sits on the Grant Assessment Panel 1 for Parkinson's UK, the Research Committee for the Cure Parkinson's Trust and the Linked Clinical Trials Committee. She has previously chaired the Data Monitoring Committee for the GDNF trial in Parkinson's disease. She is regional representative on the Association of British Neurologists Research Committee. She is a member of the Examination Board and Question Writing Group for the Neurology SCE.
Highlights
Research
Research
Research interests
Dr Carroll's current research focus is on clinical trials of neuroprotective interventions in Parkinson's disease, currently being the chief investigator of a multi-centre clinical trial of simvastatin as a potential neuroprotective therapy in PD (PD-STAT). She also has an interest in the use of technology (wearable sensors and apps) for early disease detection, personalising therapy and monitoring disease progression. She has overseen the development of a PD DNA bank (2700 samples) and a regional PD clinical research register. She was appointed National Specialty Lead for Neurodegenerative Disease in 2017. She has been PD Speciality Lead, South West Peninsula CRN since April 2014, previously being joint PD Research Director for SW DeNDRoN (2010-2014). She was Chair of the Peninsula Parkinson’s Excellence Network (PenPEN) (2015-2017).
Within University Hospitals Plymouth NHS Trust, Dr Carroll leads development of the Parkinson’s disease service, which won a Parkinson's Excellence Network Award in 2017. She also leads a successful trial delivery team, overseeing a mixed portfolio of Parkinson's clinical studies - commercial and non-commercial, interventional and observational.
Publications
Publications
Key publications
Key publications are highlighted
Journals
Articles
(2022) 'Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease' BMC Neurology 22, (1) , DOI Open access
(2022) 'Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease' JAMA Neurology , DOI Open access
(2022) 'Implications of research that excludes under-served populations' Nature Reviews Neurology 18, (8) 449-450 , DOI
(2022) 'Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT' Journal of Parkinson's Disease 1-5 , DOI Open access
(2022) 'Enhancing Trial Delivery in Parkinson’s Disease: Qualitative Insights from PD STAT' Journal of Parkinson's Disease 1-14 , DOI Open access
(2022) 'Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease' Neurodegenerative Disease Management 12, (2) 77-91 , DOI Open access
(2021) 'A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond' Trials 22, (1) , DOI Open access
(2021) 'Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study' Journal of the Neurological Sciences 429, 119426-119426 , DOI
(2021) 'Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?' Parkinsonism and Related Disorders , DOI Open access
(2021) 'Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease' Parkinson's Disease 7, (1) , DOI Open access
(2021) 'Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study' BMJ Open 11, (5) e047993-e047993 , DOI Open access
(2021) 'Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines' IEEE Journal of Biomedical and Health Informatics 25, (1) 218-226 , DOI Open access
(2020) 'Ensuring that COVID-19 Research is Inclusive - guidance from the NIHR INCLUDE project' BMJ Open 10, (11) , DOI Open access
(2020) 'Introducing the Parkinson’s KinetiGraph into Routine Parkinson’s Disease Care: A 3-Year Single Centre Experience' Journal of Parkinson's Disease 10, (4) 1827-1832 , DOI Open access
(2020) 'Developing a roadmap to improve trial delivery for underserved groups: results from a UK multi-stakeholder process' Trials , DOI Open access
(2020) 'Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities' Age and Ageing , DOI Open access
(2020) 'In reply to: Helmich and Bloem (2020) “The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities”' Journal of Parkinson's Disease 1-2 , DOI Open access
(2020) 'GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop' Journal of Parkinson's Disease 1-17 , DOI Open access
(2020) 'Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer' Journal of Parkinson's Disease 10, (2) 413-428 , DOI Open access
(2020) 'Genetic networks in Parkinson’s and Alzheimer’s disease' Aging , DOI Open access
(2020) 'Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study' Translational Neurodegeneration 9, (1) , DOI Open access
(2020) 'Genome-wide association study of pain in Parkinson's disease implicates TRPM8 as a risk factor' Movement Disorders , DOI Open access
(2019) 'A qualitative study on the impact of First Steps- a peer-led, educational intervention for people newly diagnosed with Parkinson’s Disease' Behavioral Sciences , DOI Open access
(2019) 'Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study' BMJ Open , DOI Open access
(2019) 'Impact of Quantitative Assessment of Parkinson’s Disease-Associated Symptoms Using Wearable Technology on Treatment Decisions' Journal of Parkinson's Disease 9, (3) 601-601 , DOI Open access
(2019) 'Statins and Parkinson's: A complex interaction' Movement Disorders 34, (7) 934-935 , DOI Open access
(2019) 'Discovery of Volatile Biomarkers of Parkinson’s Disease from Sebum' ACS Central Science 5, (4) 599-606 , DOI Open access
(2019) 'Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease' Molecular Brain 12, (1) 0-0 , DOI Open access
(2018) 'Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease' Movement Disorders Clinical Practice , DOI Open access
(2018) 'Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists' Neurodegenerative Disease Management Open access
(2018) 'Identification of Optimum Panel of Blood-based Biomarkers for Alzheimer’s Disease Diagnosis Using Machine Learning' 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) , DOI Open access
(2018) 'Machine-learning based identification of undiagnosed dementia in primary care: a feasibility study' BJGP Open 2, (2) 0-0 , DOI Open access
(2018) 'Exercise for people with Parkinson’s: a practical approach' Practical Neurology 18, (5) , DOI Open access
(2018) 'First comprehensive tool for screening pain in Parkinson's disease: The King's Parkinson's Disease Pain Questionnaire (KPPQ)' European Journal of Neurology 25, (10) 1255-1261 , DOI Open access
(2017) 'Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress' Journal of Parkinson's Disease , DOI Open access
(2016) 'Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease' Neurobiology of Aging 48, 222.e1-222.e7 , DOI Open access
(2016) 'Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease' 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) , DOI Open access
(2016) 'Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease' Annu Int Conf IEEE Eng Med Biol Soc 2016, 2415-2418 , DOI
(2016) 'Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis' Oncotarget , DOI Open access
(2016) 'The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) – an interim analysis of a multicentre study of the patient's perspective' Parkinsonism & Related Disorders 22, e41-e41 , DOI
(2015) 'King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation' Movement Disorders 30, (12) 1623-1631 , DOI Open access
(2015) 'LiveWell - Promoting Healthy Living and Wellbeing for Parkinson Patients Through Social Network and ICT Training: Lessons Learnt and Best Practices' International Journal of Healthcare Information Systems and Informatics
(2013) 'Molecular genetic studies of neurodegenerative disease' J Neurol Neurosurg Psychiatry 84, (11) , DOI Open access
(2013) 'Δ9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' J Neurol Neurosurg Psychiatry 84, (11) , DOI Open access
(2013) 'Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease' Acta Neuropathologica 1-7 , DOI
(2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 , DOI Open access
(2012) 'Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease' Neuropathology and Applied Neurobiology 38, (6) 535-547 , DOI
(2012) 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' Clin Med (Lond) 12, (3) 210-215 , DOI Open access
(2011) 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' Trials 12 Suppl 1, , DOI
(2011) 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, (1) 73-80 , DOI Open access
(2010) 'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon' J Neurol 257, (12) 2094-2096 , DOI
(2010) 'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease' MOVEMENT DISORDERS 25, S621-S621 Open access
(2010) 'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD' MOVEMENT DISORDERS 25, S628-S628 Open access
(2009) 'Cauda equina syndrome following a lumbar puncture' J Clin Neurosci 16, (5) 714-716 , DOI Open access
(2007) 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 , DOI
(2007) 'The feminisation of British neurology: implications for workforce planning' Clin Med (Lond) 7, (4) 339-342 , DOI Open access
(2005) 'Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS' Neurology 65, (6) 934-937 , DOI
(2005) 'Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks' JOURNAL OF NEUROSCIENCE METHODS 144, (1) 47-52 , DOI Open access
(2005) 'Muscle cramps and weakness secondary to graft versus host disease fasciitis' Eur J Neurol 12, (4) 320-322 , DOI Open access
(2005) 'Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study' Neurology 64, (6) 1100-1100 , DOI
(2004) 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 , DOI
(2004) 'The 'harlequin' sign in association with multiple sclerosis' JOURNAL OF NEUROLOGY 251, (9) 1145-1146 , DOI
(2004) 'Do on-off variations cause discrepancies in the historical items of the UPDRS?' MOVEMENT DISORDERS 19, (5) 605-605 , DOI Open access
(2004) 'The effect of cannabis on tremor in patients with multiple sclerosis' Neurology 62, (7) 1105-1109 , DOI
(2004) 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 , DOI Open access
(2004) 'Provision of 24 hour acute neurology care by neurologists: manpower requirements in the UK' J Neurol Neurosurg Psychiatry 75, (3) 406-409 , DOI Open access
(2004) 'Charles Karsner Mills (1845-1931) and his syndrome' Some Aspects of History of Neuroscience 35-36
(2004) 'Raised intracranial pressure presenting with spontaneous periorbital bruising: two case reports' Journal of Neurology, Neurosurgery and Psychiatry 75, (8) Open access
(2002) 'Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome' Movement Disorders 18, (3)
(1998) 'Glutamate antagonists for Parkinson's disease - Rationale for use and therapeutic implications' CNS DRUGS 9, (6) 421-429 , DOI
(1998) 'Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures' Brain 121, (4) 659-675 , DOI
(1998) 'The pallidotomy debate' British Journal of Neurosurgery 2, (12)
(1998) 'Visual fields in patients with posterior GPi pallidotomy'
(1997) 'Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action' Neurosci Biobehav Rev 21, (4) 469-475 , DOI Open access
(1995) 'REVERSAL OF PARKINSONIAN SYMPTOMS BY INTRASTRIATAL AND SYSTEMIC MANIPULATIONS OF EXCITATORY AMINO-ACID AND DOPAMINE TRANSMISSION IN THE BILATERAL 6-OHDA LESIONED MARMOSET' BEHAVIOURAL PHARMACOLOGY 6, (5-6) 492-507
(1995) 'NEUROCHEMICAL AND BEHAVIORAL INVESTIGATIONS OF THE NMDA RECEPTOR-ASSOCIATED GLYCINE SITE IN THE RAT STRIATUM - FUNCTIONAL IMPLICATIONS FOR TREATMENT OF PARKINSONIAN SYMPTOMS' PSYCHOPHARMACOLOGY 119, (1) 55-65 , DOI
(1993) 'Chemical signalling in the globus pallidus in parkinsonism' Progress in Brain Research (99) 125-139
Chapters
(2022) 'Co-designing Resources for Knowledge-Based Self-reflection for People Living with Parkinson’s Disease to Better Enable Independent Living' Springer Series in Design and Innovation Springer International Publishing 237-251 , DOI
(2020) 'Gene Expression Meta-Analysis of Parkinson’s disease and its Relationship with Alzheimer’s disease' Prime Archives in Molecular Biology Vide Leaf, Hyderabad , DOI
Conference Papers
(2022) 'Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Results From a 12-Month Phase 3 Study' 178-179
(2022) 'Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Results by Age, Disease Duration, and Baseline "Off" Time' 444-445
(2022) 'Interaction with Regulatory Agencies Worldwide to Advance the Use of Digital Health Technology in Parkinson's Disease Clinical Research: the Critical Path for Parkinson's Pre-Competitive 3DT Initiative' S21-S22
(2021) 'Impact of 3-month earlier versus later initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations' Elsevier BV 119447-119447 , DOI
(2021) 'Impact of 3-month early versus postponed initiation of opicapone vs entacapone in Parkinson's levodopa-treated patients' 626-627
(2021) 'Influence of levodopa daily dose in Opicapone effectiveness in Parkinson's: the real-world OPTIPARK study' 275-275
(2020) 'Not so simple: the challenge of developing a non-motor symptoms app (NMS Assist) for people with Parkinson's (PwP)' S652-S652 Open access
(2016) 'PD-TAP: AN OBJECTIVE AND AUTOMATED MEASURE OF PARKINSON'S DISEASE SEVERITY' BMJ e1.237-e1 , DOI
(2015) 'People with Parkinson's design clinical trials charter to improve communication about, recruitment to and retention in Parkinson's clinical trials' Springer Science and Business Media LLC , DOI
(2015) 'Two-arm randomised futility trials: PD-stat - a futility trial of a potential neuroprotective treatment in people with Parkinson's disease' Springer Science and Business Media LLC , DOI
(2013) 'Accumulation of alpha synuclein in the bowel in preclinical Parkinson's disease' 11-11
(2013) 'Cannabinoid receptor expression in Parkinson's disease' 34-35
(2012) 'ENDOCANNABINOID TOXICITY IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' BMJ A13.4-A14 , DOI
(2012) 'Delta(9)-THC is protective in a cell culture model of Parkinson's disease through a PPAR gamma mediated mechanism resulting in increased expression of PGC1-alpha' S39-S39
(2012) '108 Investigating the neuroprotective properties of Δ9-THC in a cell culture model of Parkinson's disease' BMJ e1.58-e1 , DOI
(2010) 'CANNABINOIDS ARE NEUROPROTECTIVE IN A HUMAN CELL CULTURE MODEL OF PARKINSON'S DISEASE' E60-E60 , DOI
(2010) 'CHANGES IN IRON-REGULATORY GENE EXPRESSION OCCUR IN HUMAN CELL CULTURE MODELS OF PARKINSON'S DISEASE' E29-E29 , DOI
(2007) 'A rare complication of a common procedure: Acute cauda equina syndrome following a lumbar puncture' 218-218
(2005) 'Childhood onset demyelinating neuropathy and cataracts: A potentially treatable disorder' 1323-1324
(2005) 'Clinical viral encephalitis in adults: A 10 year retrospective study' 157-158
(2003) 'Meeting the Association of British Neurologists guidelines: Provision of 24 hour acute neurology care by neurologists' 1453-1453
(2003) 'Stroke in Devon: The need to translate knowledge into action' 1176-1177
(2003) 'Charles Karsner Mills (1845-1931) and his syndrome' 406-406
Presentations and posters
'Home Based Care: A care pathway innovation for Parkinson's disease' Open access
'Using a Delphi process to inform the design of disease modifying trials in Parkinson's disease' Open access
'ASSOCIATION OF BRITISH NEUROLOGISTS SUSTAINABILITY SPECIAL INTEREST GROUP (ABN SUSTAINABILITY SIG): FORMATION, OBJECTIVES AND INVITATION' , DOI Open access
'Can implementation of technology transform the management of Parkinson's? Lessons learnt from the Parkinson's KinetiGraph (TM) (PKG (TM)) service evaluation project' Open access
'SONAR identifies registrar research training needs in a clinical training program'
'Successful neurology trainee research network collaborative audit'
'023 Evaluating a home-based care pathway for people with Parkinson’s disease' , DOI
'233 Working towards an adaptive trial platform for Parkinson’s disease' , DOI
'237 Designing and implementing a home based care pathway for people with Parkinson’s disease' , DOI
'109 Embedding patient voice in trial design: the EJS ACT-PD experience' , DOI
'110 Outcome and mortality of hospital admission with COVID-19 for individuals with parkinsonian syndromes' , DOI
'Artificial Intelligence based detection of Parkinson’s disease in magnetic resonance imaging brain scans'